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Mercaptobenzothiazole (MBT) compounds are well known contact allergens. To detect rubber allergic
patients we use bothMBT (2% in petrolatum) and a mercapto-mix with 4 constituents of 0.5% each in
our standard series. In this article the EECDRG presents data of in total 32 475 consecutive tested
patients attending the respective contact dermatitis clinics from 11 centres in Europe to determine if the
mix andMBTdetected the same allergic patients.We found 327 patients positive to the mix orMBT, or
to both. 261 were positive to the mix and 254 to MBT. MBT was negative in 73 patients who were
positive to the mix. If the mix had not been in the standard series, on average 22%of patients allergic to
a mercapto-compound would have been missed, for MBT this would have been on average 20%. All
clinics would have missed a significant number of positive reactions if both compounds had not been
tested. We conclude, that both the mercapto mix and MBT are required in the standard series.
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Mercaptobenzothiazole compounds are well-
known contact allergens. They can be found in
rubber products as accelerators but they are also
used as antirust agents and fungicides, e.g. in metal
working fluids and agricultural pesticides.
Mercaptobenzothiazole (MBT) 2% in petrolatum
was part of the first 20 standard patch test allergens
proposed by the ICDRG (International Contact
Dermatitis Research Group) in 1968 (1, 2). In the
1970s MBT was replaced by a mix (3, 4) which
consisted of 4 chemicals each in a concentration
of 0.25%: 2-mercaptobenzothiazole (MBT),
N-cyclohexyl-2-benzothiazyl sulfenamide, 2,20-
dibenzothiazyl disulphide and 2(4-morpholinyl)-
mercaptobenzothiazole. Some years later the
concentration of each chemical was raised to
0.5% (5). In 1979 the North American Contact
Dermatitis Group advised a mercapto-mix with-
out MBT, the concentrations of the 3 remaining 3
constituents were 0.333%. MBT itself was tested
in a concentration of 1% in petrolatum; investiga-
tions were suggestive that otherwise mercapto-
compounds allergic patients were missed (6). In
1988 the ICDRG and the EECDRG recom-
mended adding MBT 2% to the standard series
to avoid false negative reactions (7). Hansson &
Agrup (1993) (8) reported on the instability of the
mercapto-mix substances and as MBT was the
stable end-product they proposed using MBT as
the single chemical for patch testing for mercap-
tobenzothiazole/derivatives sensitivity. Shortly
afterwards Geier & Gefeller (1995) (9), using
data obtained from the Information Network of
Departments of Dermatology (IVDK) in
Germany, that the mix could be replaced by
MBT.
15 years later we are still using MBT in
combination with a mix in our standard series.
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Even the test concentrations still differ between
the American and the European series. The
EECDRG recommends MBT 2% and a mix with
4 constituents of 0.5% each, the NACDG advises
MBT 1% in combination with the mix with 3
chemicals each 0.333%. For practical reasons, the
ICDRG follows the advice of the NACDG (10).
The EECDRG reviewed their results of the
European standard series for the years 1996–2000
(11). The results of patch testing about 26 000
patients raised again the question of having both
MBT and the mercapto-mix in the standard series
as both test preparations were positive in I% of the
tested population. The data from clinics of the
EECDRG were used to determine if the mix and
MBT detected the same allergic patients.
Patients and Methods
The data was retrospectively compiled for the
period 1996 through 2000 from 11 centres in
Europe. Included were consecutive tested
patients attending the respective contact derma-
titis clinics, in total 32 475 patients.
Patch testing was performed according to the
ICDRG guidelines with the European Standard
series (e.g. MBT 2% and mercapto-mix 2%). The
results were based on the final evaluation of the
patch testing in each clinic, usually the day 3 or 4
reading. Finn chambers1 were used in 8 and Van
der Bend Square Chambers1 in 2 centres. One
centre used the TRUE Test1 system.
Results
The data of each clinic is given in Table 1: the total
number of patch-tested patients and those who
were positive for mercapto-compounds, either the
mix orMBT and the number of patient not reacting
to one of these two compounds. The quotient of
these figures gives the percentage of patients which
would not have been identified if the mix or MBT
was not included in the European Standard Series.
If the mix had not been in the standard series, on
average 22% of the patient allergic to a mercapto-
compound would have been missed. The variation
between the involved clinics ranged between 0%
and 34%. This is due to the small numbers of
positive reaction in the separate clinics. For MBT
this would have been on average 20% if this
substance had been omitted (range 0–32%).
The combined figures of the 11 clinics are
shown in Table 2. If all figures are added
together we have 327 patients positive to the
mix or MBT, or to both. 261 were positive to
the mix and 254 to MBT. MBT was negative in
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Practically all clinics would have missed a sig-
nificant number of positive reactions if both com-
pounds had not been tested. There is no
important difference between the clinic (n4)
using the TRUE Test1 system and the other
clinics.
Discussion
Our study shows clearly, in a large group of
patients (327 mercapto-compound positive
patients), that both the mercapto-mix and MBT
are required in the standard series. This confirms
other studies which also indicate that a mix in
combination with MBT is necessary to detect all
your mercapto-sensitive patients (12, 13). Missing
on an average of about 20% and 22%, respect-
ively, of sensitized patients is unacceptable.
Based on cross-reactivity studies and a study
on the stability of the compounds of the mix it
would be sufficient to test with MBT only (8, 14,
15). Several clinical studies suggested that this
may be correct and that MBT alone would suffice
(9, 16). However, our study clearly demonstrates
that a large number of patients would be needed
to be able to confirm such a conclusion.
Adding only 0.2% of patients with contact
allergy by putting an additional allergen to the
standard series does not sound reasonable (17).
However, it detects in this case an important
extra amount of rubber allergic patients. Of
course it would be better to have only one aller-
gen or mix to detect ‘all’ mercapto-allergic
patients. But, there is no alternative so far.
The test concentration of MBT, 1 or 2%, the
composition of the mercapto-mix and the con-
centration of each compound in the mix have
been changed several times since the introduction
in 1968. Extensive research into the best solution
is lacking. It would be interesting to have data
comparing the American mercapto-mix with 3
components (not including MBT) and the mix
with 4 components (including MBT) used in
Europe. The combination of 3 components in
combination with MBT as a separate test
material sounds more logical then the present
European approach.
For the moment it is advisable to continue
with European Standard Series as it is: MBT
and the mercapto-mix (4 components) both 2%
in petrolatum (18).
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Table 2. Number of patients with a positive or negative reac-
tion for mercaptobenzothiazole and the mercapto-mix in the
European standard series
MBT positive MBT negative Total
Mercapto-mix pos. 188 73 261
Mercapto-mix neg. 66 – 66
Total 254 73 327
The results are compiled from 11 clinics throughout Europe;
total number of patients tested were 32 475, out of which 327
patients were sensitized for at least one of the two Mercapto-
compounds.
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